



Antibodies Therapies against Infectious Diseases

Guest Editor:

Prof. Dr. Gary McLean

1. Molecular Immunology, School
of Human Sciences, London
Metropolitan University, London,
UK

2. Faculty of Medicine, National
Heart & Lung Institute, Imperial
College London, London, UK

Deadline for manuscript
submissions:

closed (30 May 2014)

Message from the Guest Editor

Dear Colleagues,

Approximately 30 monoclonal antibodies are currently licensed for use to treat human diseases such as cancer, autoimmune disorders, allergy and transplant rejection. However, just one monoclonal antibody (palivizumab) is licensed that targets an infectious disease pathogen (respiratory syncytial virus, RSV). Nevertheless, several antibodies (approximately 10 of 200) are undergoing preclinical development, or are in clinical trials, for viral infectious diseases. The current Special Issue welcomes contributions from experts in the field that address and review the current state-of-the art technology and developments in the field of antibody therapies against infectious diseases.

Dr. Gary McLean

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry,
Technical University of Munich,
Emil-Erlenmeyer-Forum 5, 85354
Freising (Weihenstephan),
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: CiteScore - Q1 (*Drug Discovery*)

Contact Us

Antibodies Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
[X@Antibodies_MDPI](https://twitter.com/Antibodies_MDPI)